Medication info
Glupax ER Tablets 850 mg (Metformin Hydrochloride)

Glupax ER Tablets 850 mg (Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Metformin Hydrochloride›850mg / 1 tablet
Manufacturer / importer
Darim Biotech Co., Ltd.
Appearance
White, oblong extended-release film-coated tablets
Packaging
Bottle - 100 tablets/bottle, Bottle - 30 tablets/bottle
Approval status
Active

MFDS item code 202104996 · Approved 2021.06.30 · Insurance code 664602680

Summary

Main use
Treatment of type 2 diabetes mellitus in adults
Who takes it
Adults
Adult dose
The dosage should be determined individually based on therapeutic response and tolerability and should not exceed the recommended maximum daily dose. - The usual starting dose is one 500mg extended-release metformin hydrochloride tablet once daily with the evening meal. - Blood glucose levels should be measured after one week and the dose adjusted accordingly. Gastrointestinal adverse reactions may improve with gradual dose increases. The maximum dose is 2000mg per day. - When increasing the dose, it should be increased by 500mg each week. Up to a maximum of 2000mg per day may be taken with the evening meal. If glycemic control is not achieved with a maximum of 2000mg once daily, consider taking 1000mg twice daily; both doses should be taken with meals. - For patients already receiving metformin tablets, the starting dose of this formulation is the same as the daily dose of immediate-release metformin tablets. Switching to this formulation is not recommended for patients taking more than 2000mg per day of immediate-release metformin tablets. - During initiation and dose adjustment, fasting blood glucose should be measured to assess the response to this medicine and determine the minimum effective dose. Glycated hemoglobin should be measured approximately every 3 months. - The goal of treatment with this medicine, whether administered as monotherapy or in combination with a sulfonylurea or insulin, is to reduce fasting blood glucose and glycated hemoglobin to normal or near-normal levels using the minimum effective dose. Patients with renal impairment This medicine may be used in patients with moderate stage 3a renal impairment (creatinine clearance [CrCl] 45≤~ <60ml/min or glomerular filtration rate (GFR) 45≤~ <60 mL/min/1.73 m2) who do not have other conditions that may increase the risk of lactic acidosis, with the following dosage adjustment. - The starting dose is 500mg or 750mg once daily. The maximum daily dose is 1000mg. Renal function should be monitored closely every 3- 6 months. If creatinine clearance or glomerular filtration rate decreases to below 45ml/min or 45ml/min/1.73m2, respectively, this medicine must be discontinued immediately.

Ingredients

Manufacturer
Darim Biotech Co., Ltd.

Efficacy & effects

Treatment of type 2 diabetes mellitus in adults

  • Type 2 diabetes with insufficient blood sugar control
View approved original text

This medication is used for the treatment of adult patients with type 2 diabetes whose blood sugar control is not sufficient with diet and exercise alone, particularly for overweight diabetes patients. It can be used alone or in combination with other oral hypoglycemic agents or insulin to effectively control blood sugar levels. This helps improve the patient's blood sugar levels and aids in the prevention of diabetes-related complications.

How to take

Adult dose

The dosage should be determined individually based on therapeutic response and tolerability and should not exceed the recommended maximum daily dose. - The usual starting dose is one 500mg extended-release metformin hydrochloride tablet once daily with the evening meal. - Blood glucose levels should be measured after one week and the dose adjusted accordingly. Gastrointestinal adverse reactions may improve with gradual dose increases. The maximum dose is 2000mg per day. - When increasing the dose, it should be increased by 500mg each week. Up to a maximum of 2000mg per day may be taken with the evening meal. If glycemic control is not achieved with a maximum of 2000mg once daily, consider taking 1000mg twice daily; both doses should be taken with meals. - For patients already receiving metformin tablets, the starting dose of this formulation is the same as the daily dose of immediate-release metformin tablets. Switching to this formulation is not recommended for patients taking more than 2000mg per day of immediate-release metformin tablets. - During initiation and dose adjustment, fasting blood glucose should be measured to assess the response to this medicine and determine the minimum effective dose. Glycated hemoglobin should be measured approximately every 3 months. - The goal of treatment with this medicine, whether administered as monotherapy or in combination with a sulfonylurea or insulin, is to reduce fasting blood glucose and glycated hemoglobin to normal or near-normal levels using the minimum effective dose. Patients with renal impairment This medicine may be used in patients with moderate stage 3a renal impairment (creatinine clearance [CrCl] 45≤~ <60ml/min or glomerular filtration rate (GFR) 45≤~ <60 mL/min/1.73 m2) who do not have other conditions that may increase the risk of lactic acidosis, with the following dosage adjustment. - The starting dose is 500mg or 750mg once daily. The maximum daily dose is 1000mg. Renal function should be monitored closely every 3- 6 months. If creatinine clearance or glomerular filtration rate decreases to below 45ml/min or 45ml/min/1.73m2, respectively, this medicine must be discontinued immediately.

Precautions

This medication can occasionally cause a rare but serious condition known as lactic acidosis. Lactic acidosis is a disease resulting from abnormally high levels of lactic acid in the blood, and in severe cases, it can be life-threatening. Caution is necessary when using this drug in conjunction with other diabetes medications such as insulin or sulfonylureas, as it may lead to hypoglycemia. Patients with moderate or severe renal impairment, dehydration, severe infections, acute myocardial infarction, or other acute illnesses should not use this drug. Additionally, patients with acute heart failure or those undergoing specific tests using iodine contrast agents should also avoid treatment with this medication. It is not to be used in patients with an allergy to any component of this drug or those with type 1 diabetes or diabetic ketoacidosis. Patients with severe infections or major traumas should temporarily discontinue this medication, as should those undergoing surgery, for a certain period around the procedure. Caution is also advised for patients with impaired liver function, excessive alcohol intake, dehydration, vomiting, or gastrointestinal disorders. Kidney function should be regularly monitored during treatment with this medication, and it should be discontinued if kidney function deteriorates. Patients with irregular or insufficient food intake, engaging in vigorous exercise, or taking other medications should use this drug carefully due to the increased risk of hypoglycemia or lactic acidosis. Gastrointestinal disturbances such as nausea, vomiting, diarrhea, and abdominal pain are common when starting this medication and usually resolve over time. Vitamin B12 deficiency may occur, so it is recommended to regularly check serum vitamin B12 levels. During pregnancy, consultation with a doctor is necessary as it may affect the fetus if planning for pregnancy or currently pregnant, and breastfeeding is not recommended on this medication. Elderly patients are likely to have decreased kidney function, so kidney function should be checked before and regularly monitored during treatment. In case of overdose, hypoglycemia may be uncommon, but there is a risk of lactic acidosis, requiring immediate medical attention for appropriate treatment. This drug is not recommended for individuals under 17 years old as safety and efficacy have not been established in this age group. During treatment, alcohol consumption should be avoided, and interactions with other medications should be discussed with a physician or pharmacist. The tablets should be swallowed whole and not chewed or crushed, and the tablet coating may be excreted in the stool, which is normal. Finally, this medication should be kept out of reach of children and not stored in other containers.

Side effects

  • severe lactic acidosis
  • severe hypoglycemia
  • vitamin B12 deficiency
  • taste impairment
  • nausea
  • vomiting
  • diarrhea
  • abdominal pain
  • loss of appetite
  • erythema
Show 3 more
  • pruritus
  • urticaria
  • rash

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a sealed container to protect it from air and moisture. It is advisable to maintain a storage temperature between 1 and 30 degrees Celsius in a normal environment.

Appearance and packaging

Appearance

White, oblong extended-release film-coated tablets

Package unit

Bottle - 100 tablets/bottle, Bottle - 30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.